Title: Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus
Authors: Mathieu, Chantal # ×
Issue Date: Oct-2006
Publisher: Informa Healthcare
Series Title: Expert Opinion on Drug Metabolism & Toxicology vol:2 issue:5 pages:779-791
Abstract: Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) is a prandial insulin approved in the EU and the US for the treatment of adults with diabetes. Its glycaemic control is comparable to subcutaneous insulin in Type 1 and 2 diabetes, and has superior efficacy versus oral antidiabetic agents in Type 2 diabetes. Hypoglycaemia and mild-to-moderate cough are the main side effects. The treatment group differences in pulmonary function occur early, and are small, nonprogressive for up to 2 years and reversible following discontinuation. Patient-reported outcomes data displays higher diabetes treatment satisfaction, improvements in some quality-of-life scores, and treatment preference with inhaled human insulin versus traditional means. Availability of inhaled insulin may increase insulin acceptance and thus improve glycaemic control in patients with diabetes.
ISSN: 1742-5255
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical Residents Medicine
Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science